Top

Published in:

01-02-2021 | Nerve Stimulation | Original Communication

Does pallidal neuromodulation influence cognitive decline in Huntington’s disease?

Authors: Emily Sanrey, Valérie Macioce, Victoria Gonzalez, Laura Cif, Fabienne Cyprien, Emilie Chan Seng, Philippe Coubes, Gaetan Poulen

Published in: Journal of Neurology | Issue 2/2021

Abstract

Objective

Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder associated with motor, psychiatric and cognitive deterioration over time. To date, Continuous Electrical Neuromodulation (CEN) of the globus pallidus internus (GPi) has been reported to improve chorea but little is known about cognitive progression in these patients. We propose to examine CEN impact on expected cognitive decline throughout long-term neuropsychological assessment of a cohort of HD patients.

Method

13 consecutive HD patients underwent GPi neuromodulation between January 2008 and February 2019. Over a 5-year follow-up period, they received systematic pre- and post-operative assessment according to the existing protocol in our unit. The main outcome measure was the total score obtained on the Mattis Dementia Rating Scale (MDRS) as an indicator of global cognitive function.

Results

Chorea decreased in all patients postoperatively with a mean improvement of 56% despite disease progression over time, according to previous studies. Moreover we found that the global cognitive profile of HD patients treated with CEN was stable during the first 3 years of treatment.

Conclusion

We report an unexpected positive influence of GPi continuous electrical neuromodulation on the progression of global cognitive functioning in operated HD patients. This is the most important group of patients treated with this method to our knowledge whatever the sample size remains small. This result provides promising evidence of GPi-CEN efficacy not only in reducing chorea, but also in delaying cognitive decline in HD patients operated at an early stage of the disease.

Available only for authorised users

Hebb MO, Garcia R, Gaudet P, Mendez IM (2006) Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington's disease: technical case report. Neurosurgery 58:E383 (discussion E383)PubMed

Moro E, Lang AE, Strafella AP, Poon YY, Arango PM, Dagher A, Hutchison WD, Lozano AM (2004) Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 56:290–294PubMed

Spielberger S, Hotter A, Wolf E, Eisner W, Müller J, Poewe W, Seppi K (2012) Deep brain stimulation in Huntington's disease: A 4-year follow-up case report. Mov Disord 27:806–807 (author reply 807-808)PubMed

Velez-Lago FM, Thompson A, Oyama G, Hardwick A, Sporrer JM, Zeilman P, Foote KD, Bowers D, Ward HE, Sanchez-Ramos J, Okun MS (2013) Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington's disease. Stereotact Funct Neurosurg 91:129–133PubMed

Chiken S, Nambu A (2016) Mechanism of deep brain stimulation: inhibition, excitation, or disruption? Neuroscientist 22:313–322PubMed

Biolsi B, Cif L, Fertit HE, Robles SG, Coubes P (2008) Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg 109:130–132PubMed

Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D (2001) Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc 7:33–44PubMed

Stout JC, Jones R, Labuschagne I, O'Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C (2012) Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 83:687–694PubMedPubMedCentral

Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649PubMed

10.

Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ané MN, Snowden J, Thompson J, Esmonde T, Gentry R, Moore JW, Bodner T (2003) Profile of cognitive progression in early Huntington's disease. Neurology 61:1702–1706PubMed

11.

Nagel SJ, Machado AG, Gale JT, Lobel DA, Pandya M (2015) Preserving cortico-striatal function: deep brain stimulation in Huntington's disease. Front Syst Neurosci 9:32PubMedPubMedCentral

12.

Sharma M, Deogaonkar M (2015) Deep brain stimulation in Huntington's disease: assessment of potential targets. J Clin Neurosci 22:812–817PubMed

13.

Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29:1–3PubMed

14.

Coubes P, Vayssiere N, El Fertit H, Hemm S, Cif L, Kienlen J, Bonafe A, Frerebeau P (2002) Deep brain stimulation for dystonia. Surg Tech Stereotact Funct Neurosurg 78:183–191

15.

Huntington Study Group (1996) Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 11:136–142

16.

Bachoud-Levi AC, Maison P, Bartolomeo P, Boisse MF, Dalla Barba G, Ergis AM, Baudic S, Degos JD, Cesaro P, Peschanski M (2001) Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 56:1052–1058PubMed

17.

Lavoie M, Callahan B, Belleville S, Simard M, Bier N, Gagnon L, Gagnon JF, Blanchet S, Potvin O, Hudon C, Macoir J (2013) Normative data for the Dementia Rating Scale-2 in the French–Quebec population. Clin Neuropsychol 27:1150–1166PubMed

18.

Wechsler D (2008) Wechsler adult intelligence Scale, 4th edn (WAIS IV). Pearson

19.

Van der Linden M, Coyette F, Pointrenaud J, Kalafat M, Calicis F, Wyns C, Adam S, et les membres du GREMEM (2004) L'épreuve de rappel libre/rappel indice à 16 items (RL/RI16). In: Solal (ed) L'évaluation des troubles de la mémoire. Marseille, pp 25–47

20.

Tombaugh TN (2004) Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19:203–214PubMed

21.

Cardebat D, Demonet JF, Viallard G, Faure S, Puel M, Celsis P (1996) Brain functional profiles in formal and semantic fluency tasks: a SPECT study in normals. Brain Lang 52:305–313PubMed

22.

Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P (2018) Rating scales for cognition in Huntington's disease: critique and recommendations. Mov Disord 33:187–195PubMed

23.

Peavy GM, Jacobson MW, Goldstein JL, Hamilton JM, Kane A, Gamst AC, Lessig SL, Lee JC, Corey-Bloom J (2010) Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord 25:1163–1169PubMedPubMedCentral

24.

Llebaria G, Pagonabarraga J, Kulisevsky J, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, Martinez-Corral M (2008) Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Disord 23:1546–1550PubMed

25.

Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41:689–692PubMed

26.

Wojtecki L, Groiss SJ, Hartmann CJ, Elben S, Omlor S, Schnitzler A, Vesper J (2016) Deep brain stimulation in huntington's disease-preliminary evidence on pathophysiology efficacy and safety. Brain Sci 6:38PubMedCentral

27.

Gonzalez V, Cif L, Biolsi B, Garcia-Ptacek S, Seychelles A, Sanrey E, Descours I, Coubes C, de Moura AM, Corlobe A, James S, Roujeau T, Coubes P (2014) Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. J Neurosurg 121:114–122PubMed

28.

Fasano A, Mazzone P, Piano C, Quaranta D, Soleti F, Bentivoglio AR (2008) GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. Mov Disord 23:1289–1292PubMed

29.

Kang GA, Heath S, Rothlind J, Starr PA (2011) Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease. J Neurol Neurosurg Psychiatry 82:272–277PubMed

30.

Zittel S, Tadic V, Moll CKE, Bäumer T, Fellbrich A, Gulberti A, Rasche D, Brüggemann N, Tronnier V, Münchau A (2018) Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington's disease. Parkinsonism Relat Disord 51:96–100PubMed

31.

Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett SB, Rosser A, Saft C, Südmeyer M, Ohmann C, Schnitzler A, Vesper J (2015) A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington's Disease. Front Neurol 6:177PubMedPubMedCentral

32.

Gruber D, Kuhn AA, Schoenecker T, Kopp UA, Kivi A, Huebl J, Lobsien E, Mueller B, Schneider GH, Kupsch A (2014) Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature. J Neural Transm (Vienna, Austria 1996) 121:1303–1312

33.

Loutfi G, Linder J, Hariz G-M, Hariz M, Blomstedt P (2014) Pallidal deep brain stimulation in the treatment of Huntington's chorea. Brain Disord Therapy. https://doi.org/10.4172/2168-975X.1000136CrossRef

34.

López-Sendón Moreno JL, García-Caldentey J, Regidor I, del Álamo M, García de Yébenes J (2014) A 5-year follow-up of deep brain stimulation in Huntington's disease. Parkinsonism Relat Disord 20:260–261PubMed

35.

Mason SL, Wijeyekoon R, Swain R, Ho AK, Smith EL, Sahakian B, Barker RA (2010) Cognitive follow up of a small cohort of Huntington's disease patients over a 5 year period. PLoS Curr 2:RRN1174

36.

Salthouse TA, Schroeder DH, Ferrer E (2004) Estimating retest effects in longitudinal assessments of cognitive functioning in adults between 18 and 60 years of age. Dev Psychol 40:813–822PubMed

37.

Stout JC, Queller S, Baker KN, Cowlishaw S, Sampaio C, Fitzer-Attas C, Borowsky B (2014) HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3. Mov Disord 29:1281–1288PubMed

38.

Stout JC, Glikmann-Johnston Y, Andrews SC (2016) Cognitive assessment strategies in Huntington's disease research. J Neurosci Methods 265:19–24PubMed

39.

Schramm C, Katsahian S, Youssov K, Démonet JF, Krystkowiak P, Supiot F, Verny C, Cleret de Langavant L, Bachoud-Lévi AC (2015) How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease. PLoS ONE 10:e0145842PubMedPubMedCentral

40.

Beglinger LJ, Adams WH, Fiedorowicz JG, Duff K, Langbehn D, Biglan K, Caviness J, Olson B, Paulsen JS (2015) Practice effects and stability of neuropsychological and UHDRS tests over short retest intervals in Huntington Disease. J Huntington's Dis 4:251–260

41.

Julayanont P, McFarland NR, Heilman KM (2020) Mild cognitive impairment and dementia in motor manifest Huntington's disease: classification and prevalence. J Neurol Sci 408:116523PubMed

42.

Chaganti SS, McCusker EA, Loy CT (2017) What do we know about Late Onset Huntington's Disease? J Huntington's Dis 6:95–103

43.

Baake V, Reijntjes R, Dumas EM, Thompson JC, Roos RAC (2017) Cognitive decline in Huntington's disease expansion gene carriers. Cortex 95:51–62PubMed

44.

Huntington Study G (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366–372

45.

Tedroff J, Waters S, Barker RA, Roos R, Squitieri F, Group ERS (2015) Antidopaminergic medication is associated with more rapidly progressive Huntington's Disease. J Huntington's Dis 4:131–140

46.

Unti E, Mazzucchi S, Palermo G, Bonuccelli U, Ceravolo R (2017) Antipsychotic drugs in Huntington's disease. Expert Rev Neurother 17:227–237PubMed

47.

Hart EP, Marinus J, Burgunder JM, Bentivoglio AR, Craufurd D, Reilmann R, Saft C, Roos RA (2013) Better global and cognitive functioning in choreatic versus hypokinetic-rigid Huntington's disease. Mov Disord 28:1142–1145PubMed

48.

Jacobs M, Hart EP, van Zwet EW, Bentivoglio AR, Burgunder JM, Craufurd D, Reilmann R, Saft C, Roos RA (2016) Progression of motor subtypes in Huntington's disease: a 6-year follow-up study. J Neurol 263:2080–2085PubMedPubMedCentral

49.

Hart EP, Dumas EM, Schoonderbeek A, Wolthuis SC, van Zwet EW, Roos RA (2014) Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease. Mov Disord 29:320–326PubMed

50.

Hart EP, Dumas EM, Giltay EJ, Middelkoop HA, Roos RA (2013) Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years. J Huntington's Dis 2:137–147

51.

Carlozzi NE, Tulsky DS (2013) Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol 18:212–225PubMed

52.

Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA (2009) Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord 24:574–578PubMed

53.

Delorme C, Rogers A, Lau B, Francisque H, Welter ML, Vidal SF, Yelnik J, Durr A, Grabli D, Karachi C (2016) Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns. J Neurol 263:290–298PubMed

Title: Does pallidal neuromodulation influence cognitive decline in Huntington’s disease?
Authors: Emily Sanrey
Valérie Macioce
Victoria Gonzalez
Laura Cif
Fabienne Cyprien
Emilie Chan Seng
Philippe Coubes
Gaetan Poulen
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Nerve Stimulation
Huntington's Disease
Olanzapine
Published in: Journal of Neurology / Issue 2/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10206-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Does pallidal neuromodulation influence cognitive decline in Huntington’s disease?

Abstract

Objective

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

Liliana Lubińska (1904–1990)

Comment on “Stroke in patients with SARS‑CoV‑2 infection: case series” from a London hospital experience

Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis

Dyslexia and cognitive impairment in adult patients with myotonic dystrophy type 1: a clinical prospective analysis

Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms

SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis